Breaking News Instant updates and real-time market news.

PODD

Insulet

$72.89

-0.02 (-0.03%)

, DXCM

Dexcom

$56.28

-0.04 (-0.07%)

17:51
01/18/18
01/18
17:51
01/18/18
17:51

Insulet is a favored diabetes play on business momentum, says Piper Jaffray

Piper Jaffray analyst JP McKim says he hosted calls yesterday with two Certified Diabetes Educators from a "high volume center" and learned that they expect Continuous Glucose Monitoring - CGM - to become a "standard of care" in the Type 1 market, which can reach penetration of 85% vs 40% today. The analyst says the findings support his view that CGM is set for accelerating growth. Kim also notes that the impact on Medtronic (MDT) is improving, while the business momentum at Insulet (PODD) continues. The analyst rates Insulet as his top choice, followed by Dexcom (DXCM) and Tandem Diabetes Care (TNDM) in the space, given the headline risk around Libre coverage and insufficient evidence of accelerating pump additions for the latter names respectively. Kim keeps his Overweight rating and $82 price target on Insulet.

PODD

Insulet

$72.89

-0.02 (-0.03%)

DXCM

Dexcom

$56.28

-0.04 (-0.07%)

TNDM

TNDM

MDT

Medtronic

$87.26

1.15 (1.34%)

  • 26

    Feb

  • 27

    Feb

  • 01

    Mar

PODD Insulet
$72.89

-0.02 (-0.03%)

01/08/18
01/08/18
UPGRADE
Target $80

Outperform
Insulet upgraded to Outperform on upcoming tailwinds at Raymond James
As previously reported, Raymond James upgraded Insulet (PODD) to Outperform from Market Perform and established an $80 price target. Analyst Jayson Bedford has increased confidence in estimates from several tailwinds that include a share gain opportunity in US insulin pumps following Johnson & Johnson's (JNJ) exit from the market in September, incremental Medicare reimbursement for OmniPod, potential growth as it enters new countries, and the expected launch of its new Bluetooth-enabled OmniPod and PDM, its first new product in five years.
01/08/18
RAJA
01/08/18
UPGRADE
RAJA
Outperform
Insulet upgraded to Outperform from Market Perform at Raymond James
01/07/18
PIPR
01/07/18
NO CHANGE
Target $65
PIPR
Overweight
Piper Jaffray sees Medicare covering Omnipod as incremental positive for Insulet
Piper Jaffray analyst JP McKim notes that Senator Susan Collins tweeted that Medicare will start covering Insulet's Omnipod, which he sees as an incremental win for the company but not exactly what he had expected. Specifically, CMS views Omnipod as a Part D which is what Insulet wanted but CMS does not require their Part D sponsors to include Omnipod on their formularies, McKim notes. While the Medicare door is ajar for Omnipod, the analyst believes it is not fully opened just yet as Insulet will now have to get on each plan sponsors formulary, a task that will take further time and resources. He reiterates an Overweight rating and $65 price target on the shares.
01/08/18
LEER
01/08/18
NO CHANGE
LEER
Outperform
Meaningful upside likely for Insulet in 2019, says Leerink
Leerink analyst Danielle Antalffy notes that Insulet announced that CMS has granted coverage of its OmniPod. While the analyst says this coverage decision was well expected, she believes it positions the company for potential upside to his 2018 sales estimates and sees meaningful upside likely in 2019 and beyond. Antalffy reiterates an Outperform rating on the shares.
DXCM Dexcom
$56.28

-0.04 (-0.07%)

01/04/18
BARD
01/04/18
NO CHANGE
Target $58
BARD
Neutral
Risk to Dexcom estimates may be less than feared, says Baird
Baird analyst Jeff Johnson says his channel checks indicate Abbott's (ABT) Libre will be reimbursed by Centers for Medicare & Medicaid Services using the same codes as Dexcom's (DXCM) G5, meaning at the same monthly price of $250 per patient. The analyst has long believed superior technology, or G5 over Libre, will win out at price parity. As such, he believes today's news may not be create as much near-term risk to Dexcom numbers as investors believe. The analyst, however, keeps a Neutral rating on Dexcom shares, despite today's 11% selloff. He believes longer-term CMS and commercial payer questions remain.
01/05/18
LEER
01/05/18
NO CHANGE
Target $75
LEER
Outperform
Dexcom pricing risk less bad than feared, says Leerink
Leerink analyst Danielle Antalffy says her conversation with a specialist reinforced her view that Dexcom (DXCM) will continue to warrant at least some price premium to Abbott's (ABT) Libre given its alert and alarm capabilities and what is presumably better outcomes for patients. The analyst continues to recommend buying Dexcom on yesterday's, particularly for investors with at least a six month time horizon. She reiterates an Outperform rating on the shares with a $75 price target. Antalffy sees the company's pricing risk as less bad than feared following yesterday's news of Abbott securing Medicaid approval sooner than expected for its Freestyle Libre.
01/05/18
WBLR
01/05/18
NO CHANGE
WBLR
Outperform
William Blair sees Dexcom remaining 'product-of-choice' in glucose monitoring
William Blair analyst Margaret Kaczor believes Dexcom (DXCM) will remain the "product-of-choice" in glucose monitoring after Abbott (ABT) received Medicare approval for its Freestyle Libre Flash. While the approval comes six to nine months earlier than anticipated, Abbott's broader presence will likely expand patient awareness, Kaczor tells investors in a research note. She believes Dexcom is well positioned given its alerts and alarms in this "more vulnerable patient population." The analyst keeps an Outperform rating on the shares following yesterday's selloff.
01/04/18
COWN
01/04/18
NO CHANGE
Target $70
COWN
Outperform
Dexcom selling off too much on Abbott news, says Cowen
Cowen analyst Doug Schenkel believes shares of Dexcom (DXCM) are down too much after Abbott (ABT) announced Medicare reimbursement for Libre. Given Libre's dosing claim, this development was expected, though it came three months earlier than expected, Schenkel tells investors in a research note. He believes a 10% selloff "appears disproportionate" on a three month timing swing on an expected event. The analyst keeps an Outperform rating on Dexcom with a $70 price target. The stock in late morning trading is down 11% to $51.86.
TNDM TNDM

10/05/17
PIPR
10/05/17
NO CHANGE
PIPR
J&J exit from insulin pumps a 'clear win' for Medtronic, says Piper Jaffray
After Animas, one of Johnson & Johnson's (JNJ) companies, announced that it intends to discontinue the manufacturing and sale of insulin pumps and selected Medtronic (MDT) as its transition partner, Piper Jaffray analyst Matt O'Brien called the news a "clear win" for Medtronic. For DexCom (DXCM), which has partnered with Animas, this decision is likely a modest negative, while Insulet (PODD) and Tandem (TNDM) may be able to capture some share from Animas pump patients who look for other therapeutic options, added O'Brien.
10/05/17
COWN
10/05/17
NO CHANGE
COWN
J&J exit 'great opportunity' for Insulet and Tandem, says Cowen
Cowen analyst Doug Schenkel says close to 10% of the U.S. insulin pump market is up for grabs over the next two years after Johnson & Johnson's (JNJ) Animas announced it is exiting the pump business. Medtronic (MDT) is likely to get the majority of patients initially, but the news is a "great opportunity" for Insulet (PODD) and Tandem Diabetes Care (TNDM), Schenkel tells investors in a research note. The analyst sees risk for Dexcom (DXCM), but believes the vast majority of its users will remain, regardless of pump choice.
10/10/17
WEDB
10/10/17
NO CHANGE
Target $17
WEDB
Outperform
Tandem Diabetes price target lowered to $17 from $50 at Wedbush
Wedbush analyst Tao Levy lowered his price target for Tandem Diabetes to $17 from $50 to reflect the risk of further dilution as it seeks to improve its cash position. He reiterates an Outperform rating on the shares.
11/21/17
PIPR
11/21/17
NO CHANGE
PIPR
Piper says selection for Lilly 'diabetes ecosystem' a clear positive for Dexcom
Piper Jaffray analyst Matt O'Brien said it was news to him that Eli Lilly (LLY) is developing a diabetes pump and smart pen as part of its "diabetes ecosystem" plans. The company's selection of Dexcom's (DXCM) CGM as part of their integrated system is a clear positive for Dexcom, while Lilly's launch of an integrated system in the U.S. market is a modest negative for Insulet (PODD) and Tandem Diabetes (TNDM) given it will create a competitive headwind starting in 2021, added O'Brien.
MDT Medtronic
$87.26

1.15 (1.34%)

01/04/18
01/04/18
DOWNGRADE

Underperform
Dexcom to Underperform at Northland
As previously reported, Northland analyst Suraj Kalia downgraded Dexcom (DXCM) to Underperform from Market Perform after Abbott (ABT) announced Medicare coverage for its Libre FGM. The analyst believes it undercuts Dexcom's competitive advantages, and contends that there is additional headline risk vis-a-vis Medtronic' (MDT) Guardian Connect CGM approval in the pipeline. Further, Kalia believes Dexcom's stock is bound to be under pressure over the next 12-18 months.
01/03/18
EVER
01/03/18
INITIATION
Target $92.5
EVER
Outperform
Medtronic initiated with an Outperform at Evercore ISI
Evercore ISI analyst Vijay Kumar started Medtronic with an Outperform rating and $92.50 price target. The analyst has confidence in the company's revenue growth accelerating in the second half of 2018. He finds the stock "compelling" at current share levels.
01/02/18
BOFA
01/02/18
UPGRADE
BOFA
Buy
Medtronic upgraded to Buy at BofA/Merrill
As previously reported, BofA/Merrill upgraded Medtronic to Buy from Neutral and increased its price target to $94 from $90. Analyst Bob Hopkins believes Medtronic is on the "verge" of delivering more consistent growth driven by its pipeline and manufacturing footprint reduction, which should drive multiple expansion.
01/02/18
BOFA
01/02/18
UPGRADE
BOFA
Buy
Medtronic upgraded to Buy from Neutral at BofA/Merrill

TODAY'S FREE FLY STORIES

JELD

Jeld-Wen

$37.64

0.09 (0.24%)

06:01
02/21/18
02/21
06:01
02/21/18
06:01
Earnings
Jeld-Wen reports Q4 adjusted EPS 26c, consensus 42c »

Reports Q4 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Feb

  • 21

    Feb

  • 28

    Mar

AMZN

Amazon.com

$1,468.35

19.66 (1.36%)

06:00
02/21/18
02/21
06:00
02/21/18
06:00
Periodicals
Amazon tried to buy smart lock maker August Home for $100M, The Information says »

Amazon tried to buy smart…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Feb

  • 18

    Mar

VRX

Valeant

$18.58

-0.3 (-1.59%)

, TEVA

Teva

$19.98

-0.92 (-4.40%)

05:55
02/21/18
02/21
05:55
02/21/18
05:55
Recommendations
Valeant, Teva analyst commentary  »

Deutsche sees rifamycin…

VRX

Valeant

$18.58

-0.3 (-1.59%)

TEVA

Teva

$19.98

-0.92 (-4.40%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Feb

  • 13

    May

  • 18

    Jun

  • 27

    Aug

BT

BT Group

$16.24

0.05 (0.31%)

05:49
02/21/18
02/21
05:49
02/21/18
05:49
Upgrade
BT Group rating change  »

BT Group upgraded to Hold…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Mar

VLVLY

Volvo AB

$19.42

-0.03 (-0.15%)

05:47
02/21/18
02/21
05:47
02/21/18
05:47
Initiation
Volvo AB initiated  »

Volvo AB initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TSE

Trinseo

$78.85

-2.2 (-2.71%)

05:44
02/21/18
02/21
05:44
02/21/18
05:44
Recommendations
Trinseo analyst commentary  »

Trinseo valuation…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NBL

Noble Energy

$29.12

2.84 (10.81%)

05:42
02/21/18
02/21
05:42
02/21/18
05:42
Recommendations
Noble Energy analyst commentary  »

Noble Energy price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Feb

  • 27

    Feb

  • 28

    Feb

05:40
02/21/18
02/21
05:40
02/21/18
05:40
General news
FX Action: USD-CAD clocked a 12-day high »

FX Action: USD-CAD…

PTLA

Portola Pharmaceuticals

$48.22

0.53 (1.11%)

05:34
02/21/18
02/21
05:34
02/21/18
05:34
Recommendations
Portola Pharmaceuticals analyst commentary  »

Portola selloff overdone…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Feb

  • 04

    May

MRK

Merck

$54.98

-1.31 (-2.33%)

05:34
02/21/18
02/21
05:34
02/21/18
05:34
Hot Stocks
Merck to acquire Viralytics for about $394M »

Merc and Viralytics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Mar

  • 25

    Mar

  • 03

    Apr

  • 04

    Apr

  • 23

    Apr

  • 23

    Apr

  • 23

    Oct

BHVN

Biohaven Pharmaceutical

$29.58

-0.03 (-0.10%)

, CTLT

Catalent

$42.48

-0.89 (-2.05%)

05:30
02/21/18
02/21
05:30
02/21/18
05:30
Hot Stocks
Biohaven Pharmaceutical announces exclusive license with Catalent »

Biohaven Pharmaceutical…

BHVN

Biohaven Pharmaceutical

$29.58

-0.03 (-0.10%)

CTLT

Catalent

$42.48

-0.89 (-2.05%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Feb

  • 21

    Feb

  • 21

    Feb

  • 04

    Mar

  • 03

    May

BHP

BHP Billiton

$46.55

-2.14 (-4.40%)

, RIO

Rio Tinto

$56.27

-1.55 (-2.68%)

05:30
02/21/18
02/21
05:30
02/21/18
05:30
Downgrade
BHP Billiton, Rio Tinto rating change  »

BHP Billiton downgraded…

BHP

BHP Billiton

$46.55

-2.14 (-4.40%)

RIO

Rio Tinto

$56.27

-1.55 (-2.68%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Feb

VJET

voxeljet

$4.00

-0.534 (-11.79%)

05:27
02/21/18
02/21
05:27
02/21/18
05:27
Recommendations
voxeljet analyst commentary  »

voxeljet making progress…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BLDP

Ballard Power

$3.29

-0.08 (-2.37%)

05:27
02/21/18
02/21
05:27
02/21/18
05:27
Hot Stocks
Ballard Power receives follow-on purchase order from Nisshinbo Holdings »

Ballard Power Systems…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Feb

  • 01

    Mar

  • 11

    Mar

  • 29

    Mar

  • 23

    May

NFLX

Netflix

$278.55

0.03 (0.01%)

05:24
02/21/18
02/21
05:24
02/21/18
05:24
Recommendations
Netflix analyst commentary  »

Netflix price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Feb

  • 26

    Feb

  • 20

    Mar

SMCI

Super Micro Computer

$18.85

-0.25 (-1.31%)

05:19
02/21/18
02/21
05:19
02/21/18
05:19
Hot Stocks
Super Micro Computer receives non-compliance letter from Nasdaq »

Super Micro Computer…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LXFT

Luxoft

$43.55

0.1 (0.23%)

, AMZN

Amazon.com

$1,468.35

19.66 (1.36%)

05:18
02/21/18
02/21
05:18
02/21/18
05:18
Recommendations
Luxoft, Amazon.com analyst commentary  »

Luxoft 20% share pullback…

LXFT

Luxoft

$43.55

0.1 (0.23%)

AMZN

Amazon.com

$1,468.35

19.66 (1.36%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Feb

  • 18

    Mar

PSA

Public Storage

$186.31

-2.44 (-1.29%)

05:17
02/21/18
02/21
05:17
02/21/18
05:17
Hot Stocks
Public Storage announces CEO, CFO succession plan »

Public Storage announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Feb

NBL

Noble Energy

$29.12

2.84 (10.81%)

05:15
02/21/18
02/21
05:15
02/21/18
05:15
Recommendations
Noble Energy analyst commentary  »

Noble Energy price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Feb

  • 27

    Feb

  • 28

    Feb

ALLE

Allegion

$85.66

2.94 (3.55%)

05:12
02/21/18
02/21
05:12
02/21/18
05:12
Recommendations
Allegion analyst commentary  »

Allegion price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MTCH

Match Group

$42.10

0.54 (1.30%)

05:10
02/21/18
02/21
05:10
02/21/18
05:10
Downgrade
Match Group rating change  »

Match Group downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MOS

Mosaic

$26.76

1.33 (5.23%)

05:07
02/21/18
02/21
05:07
02/21/18
05:07
Upgrade
Mosaic rating change  »

Mosaic upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Feb

  • 25

    Feb

  • 28

    Feb

FOGO

Fogo De Chao

$15.55

3 (23.90%)

05:06
02/21/18
02/21
05:06
02/21/18
05:06
Downgrade
Fogo De Chao rating change  »

Fogo De Chao downgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CCT

Corporate Capital Trust

$14.63

-0.12 (-0.81%)

05:04
02/21/18
02/21
05:04
02/21/18
05:04
Initiation
Corporate Capital Trust initiated  »

Corporate Capital Trust…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Mar

INOV

Inovalon

05:01
02/21/18
02/21
05:01
02/21/18
05:01
Hot Stocks
Inovalon announces resignation of CFO, COO Christopher Greiner »

Inovalon announced last…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Feb

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.